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Abstract
Background
During 2015–16 Brazil experienced the largest epidemic of Zika virus ever reported. This
arthropod-borne virus (arbovirus) has been linked to Guillain-Barre´ syndrome (GBS) in
adults but other neurological associations are uncertain. Chikungunya virus has caused out-
breaks in Brazil since 2014 but associated neurological disease has rarely been reported
here. We investigated adults with acute neurological disorders for Zika, chikungunya and
dengue, another arbovirus circulating in Brazil.
Methods
We studied adults who had developed a new neurological condition following suspected
Zika virus infection between 1st November 2015 and 1st June 2016. Cerebrospinal fluid
(CSF), serum, and urine were tested for evidence of Zika, chikungunya, and dengue
viruses.
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Results
Of 35 patients studied, 22 had evidence of recent arboviral infection. Twelve had positive
PCR or IgM for Zika, five of whom also had evidence for chikungunya, three for dengue, and
one for all three viruses. Five of them presented with GBS; seven had presentations other
than GBS, including meningoencephalitis, myelitis, radiculitis or combinations of these syn-
dromes. Additionally, ten patients positive for chikungunya virus, two of whom also had evi-
dence for dengue virus, presented with a similar range of neurological conditions.
Conclusions
Zika virus is associated with a wide range of neurological manifestations, including central
nervous system disease. Chikungunya virus appears to have an equally important associa-
tion with neurological disease in Brazil, and many patients had dual infection. To understand
fully the burden of Zika we must look beyond GBS, and also investigate for other co-circulat-
ing arboviruses, particularly chikungunya.
Author summary
During 2015–16, Brazil experienced the largest outbreak of the mosquito-borne Zika
virus ever reported and saw a subsequent increase in cases of Guillain-Barre´ syndrome
(GBS), a disorder of the peripheral nervous system (nerves outside the brain and spinal
cord) that can result in paralysis and sometimes death. In this assessment of adults pre-
senting with suspected Zika virus-associated neurological disease in Rio de Janeiro, Brazil,
we add to the growing body of evidence linking Zika to a wider range of neurological dis-
ease, including disease of the central nervous system (brain and spinal cord). We also
show that many patients initially thought to have neurological disease associated with
Zika virus were in fact infected with chikungunya virus, another arthropod-borne virus
(arbovirus) that is also associated with a wide range of neurological disease. Importantly,
many patients had evidence of infection with more than one virus. We discuss the chal-
lenges in diagnosing the infections and how different body fluid samples can be used to
help facilitate this. Our results suggest that clinicians and public health officials must look
beyond GBS if we are to understand fully the disease burden of Zika virus. In addition, we
highlight the need to investigate patients with acute neurological syndromes for other co-
circulating arboviruses, particularly chikungunya.
Introduction
Zika virus is an arthropod-borne virus (arbovirus) first isolated in Uganda in 1947, which
spread to cause large outbreaks in Micronesia in 2007, French Polynesia in 2014 and Latin
America from 2015.[1] By December 2015, it had caused an estimated 04–13 million cases in
Brazil alone.[2] Like the related dengue viruses, Zika is a flavivirus (genus Flavivirus, family
Flaviviridae) that causes a fever-arthralgia-rash syndrome and is transmitted principally by
Aedes mosquitoes. An apparent association between Zika virus and an increase in severe con-
genital disease and other neurological disorders, particularly Guillain-Barre´ syndrome (GBS),
[3–6] prompted the World Health Organisation to declare Zika virus a public health emer-
gency of international concern in February 2016.[7]
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A carefully conducted case-control study of the French Polynesian outbreak showed an
association between Zika virus infection and GBS,[4] although prior dengue exposure made
interpretation of the virology results challenging because of serological cross reactivity between
flaviviruses.[8] Dengue, like other flaviviruses including Japanese encephalitis and West Nile
viruses, can also cause both peripheral and central nervous system (CNS) disease.[9] Second-
ary dengue infections are associated with more severe dengue disease, and some have postu-
lated that prior dengue may predispose to more severe Zika infection. More recently, a study
from Colombia has shown a strong temporal association between GBS and Zika virus, with
viral RNA detected in samples from 17 patients.[5] A few case reports have described Zika
virus-associated myelitis,[10] encephalitis,[11, 12] meningoencephalitis,[13] acute dissemi-
nated encephalomyelitis,[14] Miller-Fisher syndrome,[15] and myasthenia gravis,[16] suggest-
ing that the spectrum of neurological disease may be broader than initially thought. A
preliminary epidemiological report from the French Polynesian outbreak indicated a possible
increase in other neurological manifestations associated with Zika virus, but gave few details.
[17]
Chikungunya is another arbovirus also identified in Africa in the 1950s that has spread to
cause epidemics in the tropics in recent years.[18] It was first reported in Latin America in
2013 and has caused large outbreaks in Brazil in the last two years, with over 260,000 suspected
cases in 2016.[19] Like Zika and dengue viruses, it is transmitted by Aedes mosquitoes and
leads to a fever-arthralgia-rash syndrome; it also occasionally presents with neurological dis-
ease, including GBS, encephalitis and myelitis,[20] although there are few such reports from
South America.[21] Because chikungunya is an alphavirus (genus Alphavirus, family Togaviri-
dae) there is no serological cross reactivity with the flaviviruses, making diagnosis more
straightforward. Although chikungunya virus co-circulates in many Zika-affected areas,
including Colombia and Brazil, and can cause neurological disease, its role has not been
assessed.
To assess the spectrum of neurological disease associated with Zika virus, we studied adults
in Rio de Janeiro with acute neurological syndromes following suspected Zika virus infection.
Given their similarities and co-circulation, we also investigated for chikungunya and dengue
viruses.
Methods
We studied patients who had developed a new neurological condition associated with sus-
pected Zika virus infection, whose samples had been submitted to the Flavivirus Reference
Laboratory of the Instituto Oswaldo Cruz (Fiocruz), Rio de Janeiro.
Ethics statement
The study protocol was approved by the Comitê de E´tica em Pesquisa do Instituto Nacional de
Infectologia Evandro Chagas (reference 59254116.0.1001.5262). Patient-identifying data was
anonymised.
Study population
We studied patients admitted in 11 hospitals (appendix) in Rio de Janeiro from 1st November
2015 to 1st June 2016, who had presented with an acute neurological condition associated with
a suspected Zika virus infection, as identified by fever, arthralgia or rash illness in the preced-
ing three months. In this evolving epidemic situation we used three approaches to identify
patients: using the laboratory database, we retrospectively identified 29 patients who had had
either cerebrospinal fluid (CSF) regardless of indication, or serum and/or urine in the context
The range of neurological disease associated with Zika and chikungunya viruses in adults
PLOS Neglected Tropical Diseases | https://doi.org/10.1371/journal.pntd.0006212 February 12, 2018 3 / 20
of neurological disease, sent to the laboratory for Zika virus diagnostics; additionally, clinicians
from our study hospitals identified six further patients, whose CSF sample was not on the data-
base and whose serum and/or urine request forms did not have an indication (Fig 1). Patients
under the age of 12 months were excluded.
Clinical information was obtained from case notes and discussion with the patients’ clini-
cians and documented on standardised case report forms by a member of the study team. The
information obtained included demographics, past medical history, admission history, exami-
nation, investigations, diagnosis, and management. Investigations included brain and spine
imaging for patients with suspected central nervous system infection, and nerve conduction
studies with or without electromyography for those with peripheral disease. Nerve conduction
study results were reviewed by an independent expert neurophysiologist to ensure consistency.
The Brighton criteria were used to indicate the level of certainty for diagnosing GBS and simi-
lar criteria were applied for radiculitis, encephalitis, myelitis, and meningitis (appendix). We
determined whether patients had peripheral nervous system disease (GBS, radiculitis), CNS
disease (encephalitis, myelitis, meningitis) or both.
Laboratory testing
CSF, serum, and urine samples were tested for evidence of Zika, chikungunya, and dengue
virus infection at the Fiocruz Flavivirus Laboratory. We considered detection of viral RNA
and/or IgM-specific antibody in the CSF as evidence of recent CNS infection as previously;
[22] IgM antibody in the serum, or RNA in the serum or urine was taken as evidence of sys-
temic infection.
An expanded protocol based on the interim recommendations from the WHO for labora-
tory testing for Zika virus was followed:[23] RNA was extracted from 140μl of CSF, serum, and
urine samples and eluted in 50μl using the Qiamp Mini Elute Virus Spin Kit from Qiagen (Bra-
zil). The CSF, serum, and urine samples were tested by qRT-PCR for detection of Zika, chi-
kungunya, and dengue virus RNA as described previously.[24] Serum IgM and IgG antibodies
to Zika virus NS1 antigen and serum and CSF IgM and IgG antibodies to chikungunya virus
were measured using commercial ELISAs (Euroimmun, Luebeck, Germany), according to the
manufacturer’s protocol.[25–27] CSF IgM antibodies to Zika virus were measured using a rec-
ommended capture ELISA based on the US Centers for Disease Control and Prevention
(CDC) emergency use authorization protocol (CDC Fort Collins, CO, USA).[28] Serum and
CSF IgM and IgG antibodies to dengue virus were measured using commercial ELISAs (Pan-
bio, Brazil). For serum samples with sufficient volume remaining, anti-ganglioside antibodies,
which are associated with GBS and other autoimmune neuropathies, were tested by ELISA
(Bu¨hlmann-Gangliocombi, Scho¨nenbuch, Switzerland) following the manufacturer’s
instructions.
Statistical analysis
The median time from illness onset to the development of neurological symptoms was com-
pared for those with CNS and peripheral nervous system disease, and for those with or without
CNS Zika virus infection, using the Wilcoxon-Mann-Whitney U-test.
Results
We identified 35 patients with new neurological disease associated with a suspected Zika virus
infection. Evidence for recent arbovirus infection was found in 22 (63%) of them. Table 1 and
Fig 2 show the virological diagnosis for each patient, taking into account any potential serolog-
ical cross-reactivity between flaviviruses.
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Twelve (34%) had evidence of Zika virus infection. Three (9%) with evidence of Zika virus
infection alone presented with GBS (two patients) or encephalitis (one). Nine (26%) with evi-
dence of Zika also had evidence for another arbovirus; five with chikungunya, three with den-
gue, one with both chikungunya and dengue. Three of them presented with GBS, including
one with the facial diplegia and paraesthesia variant, and six had CNS infection, predomi-
nantly encephalitis and/or myelitis. Ten patients (29%) negative for Zika had evidence for
another arboviral infection; eight with chikungunya and two with chikungunya and dengue.
Two of these presented with GBS and eight with CNS disease.
The remaining 13 patients (37%), with no evidence of a recent Zika, chikungunya, or den-
gue virus infection, presented with GBS (six patients) or CNS disease (seven). Their diagnoses
are given in the appendix, but they are not considered further here.
Clinical features
All 22 patients with evidence of recent arbovirus infection were Brazilian nationals with no
recent travel history, from 18 different districts of Rio de Janeiro. The median (range) age was
515 (17–84) years. The male:female ratio was 1:1. Their individual clinical features are sum-
marised in Table 2 and a detailed example of a clinical case, patient 9, is described in Box 1.
The seven patients with GBS all had a preceding febrile and/or rash syndrome, which was a
median (range) 12 (5–41) days before the neurological presentation; there was no statistically
significant difference in prodrome length between those with and without CNS Zika infection.
The presentations for six patients were similar—typically paraesthesia (five patients) with a
rapidly ascending symmetrical flaccid paralysis, involving all four limbs in five patients, or the
legs only in one (patient 5). Another (patient 4) presented with a GBS variant, with bilateral
lower motor neuron facial nerve palsies and paraesthesia in all four limbs.
Fig 1. Study population of patients with neurological disease associated with suspected Zika virus infection. These patients did not appear in the laboratory
database search because their CSF sample was not recorded on the database and no clinical information was included in request forms for serum and/or urine. They
were identified by the clinicians who had previously managed their care in our study hospitals.
https://doi.org/10.1371/journal.pntd.0006212.g001
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Table 1. Virological evidence for Zika, chikungunya and/or dengue virus infection in 22 patients presenting with acute neurological disease, ordered by date of
admission.
Patient Zika Chikungunya Dengue Other CSF
investigations
Virological
DiagnosisCSF
PCR
CSF
IgM
Serum
PCR
Serum
IgM
Urine
PCR
CSF
PCR
CSF
IgM
Serum
PCR
Serum
IgM
Urine
PCR
CSF
PCR
CSF
IgM
Serum
PCR
Serum
IgM
Urine
PCR
1 - + - - + - - - - - - + - + - Neg: MCS,
HSV, VDRL,
CRAG
Zika-CNS
+/- Dengue-
CNS †
2 - + - - - - - - + - - + - + - na Zika-CNS or
Dengue-CNS
or both,
Chik-Syst
3 - + + - + - - - - - - - - + - Neg: HSV Zika-CNS
+/- Dengue-
Syst †
4 + + - - na + - + - na - - - - na Neg: MCS Zika/Chik-
CNS
5 - + - - + - - - - - - - - - - Neg: MCS,
VDRL
Zika-CNS
6 na na - - - na na - + - na na - + - Neg: MCS,
VDRL
Chik/
Dengue-Syst
7 - + - + - - - - - - - - - + - na Zika-CNS or
Dengue-Syst
or both
8 - - - - - + - - - - - - - - - Neg: MCS Chik-CNS
9 - + na na na + + na na na - - na na na Neg: HSV Zika/Chik-
CNS
10 - + - + + - - - - - - na - - - Neg: MCS Zika-CNS
11 - - - - - + + - + + - - - - - Neg: MCS,
VDRL
Chik-CNS
12 - - na na - + + na na - - - na na - na Chik-CNS
13 - - - - - + - + + - - - - - - Neg: MCS,
VDRL, CRAG,
CMV/VZV/
HSV
Chik-CNS
14 - - na na na + - na na na - - na na na na Chik-CNS
15 - - na na na + - na na na - - na na na Neg: HSV Chik-CNS
16 + + na na - + + na na - - - na na - na Zika/Chik-
CNS
17 na na - - + na na + - - na na - - - Pos: VDRL Zika/Chik-
Syst
18 - - na na + + + na na - - - na na - Neg: HSV Chik-CNS,
Zika-Syst
19 - - - - - + + + + - - - - + - na Chik-CNS,
Dengue-Syst
20 - - - - - - - + + + - - - - - na Chik-Syst
21 - - - - - - - - + + - - - - - Neg: MCS,
VDRL
Chik-Syst
22 - + - - - - - - - - - - - - - na Zika-CNS
"+" = positive, "-" = negative, "na" = sample not available or inadequate volume; PCR = polymerase chain reaction; CSF = cerebrospinal fluid; MCS = microscopy,
culture and sensitivity; HSV = herpes simplex virus, CMV = cytomegalovirus, VZV = varicella zoster virus, VDRL = venereal disease research laboratory (syphilis),
CRAG = cryptococcal antigen, Chik = chikungunya; CNS = virus detected in central nervous system, Syst = virus detected systemically (i.e. outside CNS) only. Zika
virus PCR primers used: 1086–1102, 1107–1137.[24] See appendix for antibody levels, IgG results and time between infection and sample collection.
Preliminary information for this patient has previously been published.
†These patients had PCR evidence of Zika virus infection, with serological evidence of dengue infection potentially secondary to cross-reactivity.
https://doi.org/10.1371/journal.pntd.0006212.t001
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Fig 2. Venn diagram for 22 patients showing virological evidence of CNS or systemic infection with Zika, chikungunya and/or dengue, and clinical
presentation with CNS or peripheral nervous system disease. We distinguish virological evidence of CNS or systemic infection (based on PCR/
antibody testing) from clinical evidence of CNS or peripheral nervous system disease (based on clinical features). Patients in the inner darker circles have
The range of neurological disease associated with Zika and chikungunya viruses in adults
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Fifteen patients presented with CNS disease, including encephalitis and/or myelitis, with or
without involvement of the meninges or peripheral nerves. All had a febrile or rash syndrome,
many with arthralgia and malaise. The median (range) time delay between this systemic illness and
neurological disease was 4 (0–27) days; for these patients with CNS disease, there was no statistically
significant difference in prodrome length between those with and without CNS Zika infection.
The eight patients with encephalitis (with or without other CNS disease) had a median
(range) Glasgow Coma Scale score of 135 (3–15); six were confused, and two had seizures.
One patient had a supranuclear gaze palsy; two had facial weakness and four had difficulties
with speech or swallowing. The ten patients with myelitis (with or without encephalitis) com-
prised five with paraparesis (one spastic, two flaccid, and two with normal tone), four with
quadraparesis (two spastic, two flaccid) and one with a triparesis. Seven of these patients had a
sensory level, six had urinary retention and three had urinary incontinence. Three patients
with flaccid paresis had signs and symptoms compatible with transverse myelitis, namely a
sensory level and urinary retention. However, one patient with encephalomyelitis with flaccid
areflexic quadraparesis (patient 9) had extensive imaging changes in the anterior of the cord
consistent with poliomyelitis-like anterior horn cell damage.
Neurophysiological studies (see below) confirmed the involvement of lower motor neurons
for four patients with myelitis: two of those with flaccid paraparesis, one with flaccid quadra-
paresis, and one with paraparesis and normal tone. The clinical characteristics of the patients
with central, peripheral, and mixed nervous system disease are compared in Table 3.
Virology and serology
Zika virus RNA was detected in two CSF, one serum and six urine samples (from eight
patients); Zika IgM was detected in 10 CSF and two serum samples (10 patients). Chikungunya
virus RNA was detected in 11 CSF, six serum, and three urine samples (14 patients); chikungu-
nya IgM was detected in six CSF and seven serum samples (11 patients). Dengue virus RNA
was not found; dengue IgM was found in two CSF and six serum samples (six patients).
As expected, many patients had serum IgG against dengue virus, consistent with prior expo-
sure (appendix). Of the 13 patients with no evidence of recent arbovirus infection, serum Zika
virus IgG was detected in four. Anti-GM1, GD1a, GD1b and GQ1b antibodies were found in
the serum of patients with both peripheral and central nervous system disease (Table 2).
Investigations
Ten out of the 22 patients had a CSF pleocytosis (5/μL, all showing predominantly lympho-
cytes/monocytes) and 15 had a CSF protein above 045 g/L. Four patients had a mild thrombo-
cytopenia and seven had a peripheral leucocytosis, but none had leucopenia. Imaging studies
are detailed in Table 2, with examples shown in Fig 3. High signal changes were found in the
cervical (four patients) and thoracic (two) cord, brainstem (two), cerebellar peduncles (two)
and cortex (three); demyelination of the parietal cortex and thalamus was reported in patient
20 and pachymeningeal enhancement in patient 9. Three different neurophysiological patterns
were seen in patients with peripheral involvement—acute motor axonal neuropathy (AMAN),
acute motor and sensory axonal neuropathy (AMSAN) and acute inflammatory demyelinating
polyneuropathy (AIDP) (see appendix for original data). AMAN and AMSAN were seen in
patients both with and without probable Zika virus infection; AIDP was seen only in one
patient with CNS chikungunya virus infection.
evidence of CNS +/- systemic infection with the respective virus. Those in the outer paler circles have evidence of only systemic infection with the
respective virus. Note that patients 1 and 3 had confirmed Zika, +/- dengue; patients 2 and 7 had Zika or dengue or both.
https://doi.org/10.1371/journal.pntd.0006212.g002
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Table 2. Individual clinical features of 22 patients presenting with neurological disease associated with Zika, chikungunya and/or dengue virus infection, ordered
by date of admission.
Patient Virological
Diagnosis
Systemic
Features
Prodrome
Length
(days)
Neurological Features CSF
WCC
CSF
Protein
Anti-
ganglioside
Antibody
Neurological
Diagnosis (levels
of certainty)
Management Progress and
Outcome
1 (F/
47)
Zika-CNS
+/- Dengue-
CNS
Rash,
arthralgia,
malaise
4 Confusion, dysarthria,
drowsiness; paraparesis;
GCS 3; CT head—
diffuse white matter
hypodensities
10 111 GM1 Encephalitis (I) Mannitol ICU; intubated;
patient rapidly
deteriorated and
diedWCC 80
2 (F/
59)
Zika-CNS or
Dengue-CNS
or both,
Chik-Syst
Fever, rash,
arthralgia
7 UL and LL paraesthesia;
spastic quadraparesis;
extensor plantars;
impaired UL and LL
LT, PP, Vi, Pr; urinary
retention; GCS 15; MRI
spine—intramedullary
signal abnormality
involving cervical and
thoracic cord; MRI
brain—normal; NP—
normal
4 036 GM1, GD1a,
GD1b
Myelitis (I) IVIG; steroids
x 2
Developed
pulmonary
oedema on IVIG;
responded to
steroids, mRS 3
at 4 months
WCC 81
3 (M/
26)
Zika-CNS
+/- Dengue-
Syst
Fever 1 Confusion; truncal, UL
and LL paraesthesia and
numbness; spastic
hyperreflexic
quadraparesis; T5
sensory level; LMN
facial nerve and
supranuclear gaze
palsies; impaired UL
and LL LT, PP, Vi, Pr;
urinary incontinence;
GCS 13; MRI brain and
spine—signal
abnormality involving
cerebellar peduncles,
medulla and
intramedullary cervical
cord
100 112 GM1, GD1a,
GD1b
Encephalo-
myelitis (I,I)
IVIG; steroids ICU; intubated;
improved, mRS 1
at 4 months
4 (M/
34)
Zika/Chik-
CNS
Rash 12 UL and LL paraesthesia;
mild ataxia; bilateral
LMN facial nerve palsy;
hyperreflexic LL; GCS
15; MRI brain—
gadolinium
enhancement of
bilateral facial nerves;
NP—normal
2 069 - GBS variant
(facial diplegia
with paraesthesia)
IVIG Improved, full
recovery at 2
months
5 (F/
41)
Zika-CNS Fever, rash,
malaise
5 LL and peri-orbital
paraesthesia;
normotonic areflexic
paraparesis; impaired
LL LT, PP, Vi; GCS 15;
CT brain—normal
0 207 na GBS (II) IVIG Improved (extent
unknown)
WCC 218
6 (F/
30)
Chik/
Dengue-Syst
Fever, rash,
malaise
27 LL paraesthesia;
normoreflexic
paraparesis; urinary
retention; GCS 15; MRI
brain and spine—
normal; NP—normal
0 021 - Myelitis (II) IVIG; steroids Improved (extent
unknown)
WCC 93
(Continued)
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Table 2. (Continued)
Patient Virological
Diagnosis
Systemic
Features
Prodrome
Length
(days)
Neurological Features CSF
WCC
CSF
Protein
Anti-
ganglioside
Antibody
Neurological
Diagnosis (levels
of certainty)
Management Progress and
Outcome
7 (F/
66)
Zika-CNS or
Dengue-Syst
or both
Fever,
arthralgia,
malaise
13 UL and LL paraesthesia;
flaccid areflexic
quadraparesis; bilateral
LMN facial nerve palsy;
impaired UL and LL
LT, PP, Vi; GCS 15; NP
—AMSAN
0 095 GD1a GBS (I) IVIG ICU; intubated;
improved at 1
week (extent
unknown)WCC 77
8 (M/
20)
Chik-CNS Fever 0 R UL and LL
paraesthesia and
triparesis (L UL
spared), hyperreflexic
LL; impaired LL LT, PP,
Vi, Pr; C6 sensory level;
urinary retention; GCS
15; MRI spine—signal
abnormality involving
cervical and thoracic
cord; MRI brain
normal; NP—normal
0 029 - Myelitis (I) Steroids x 2 Improved, mRS
2 at 3 weeksWCC 154
9 (F/
80)
Zika/Chik-
CNS
Fever, rash,
arthralgia,
malaise
5 Headache, confusion;
flaccid hyporeflexic
quadraparesis; GCS 14;
MRI brain and spine—
signal abnormality
involving anterior
medulla, anterior
cervical and thoracic
cord, temporal lobes,
amygdala, small area
adjacent to temporal
horn of L lateral
ventricle,
pachymeningeal
enhancement
117 174 na Encephalo-
myelitis (I,I) with
subclinical
meningitis
IVIG ICU; developed
sacral
osteomyelitis;
improved, mRS 4
at 2 months
PLT 134
WCC 75
10 (M/
38)
Zika-CNS Fever, rash,
malaise
10 LL paraesthesia; flaccid
areflexic quadraparesis;
L LMN facial nerve
palsy; impaired LL Pr;
GCS 15
1 172 - GBS (II) IVIG;
antivirals
ICU; intubated,
ventilator-
associated
pneumonia;
improved (extent
unknown)
PLT 220
WCC 140
11 (M/
76)
Chik-CNS Rash,
arthralgia
0 2 seizures; confusion,
dysarthria, headache,
neck stiffness; spastic
paraparesis; extensor
plantars, palmomental
reflex; LL neuropathic
pain; T2-3 sensory level;
urinary incontinence;
GCS 14
80 145 GD1a Meningo-
encephalo-
myelitis (III,I,III)
Antivirals;
antibiotics
Unknown
outcome
PLT 254
WCC 130
(Continued)
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Table 2. (Continued)
Patient Virological
Diagnosis
Systemic
Features
Prodrome
Length
(days)
Neurological Features CSF
WCC
CSF
Protein
Anti-
ganglioside
Antibody
Neurological
Diagnosis (levels
of certainty)
Management Progress and
Outcome
12 (M/
63)
Chik-CNS Fever, rash,
arthralgia,
malaise
2 LL paraesthesia; flaccid
areflexic paraperesis; T4
sensory level; urinary
retention; fell with
intracranial injury; GCS
15 on admission, 12
after fall; CT brain
normal, MRI brain and
spine normal; NP—
AMSAN
0 092 - Myeloradiculitis
(II)
IVIG ICU, intubated
(after fall and
head injury); no
improvement;
mRS 5 at 2
months
PLT 116
WCC 65
13 (F/
51)
Chik-CNS Fever,
arthralgia,
malaise
6 Confusion, 1 x seizure,
drowsiness, dysarthria;
GCS 3; CT head normal
11 045 GQ1b Encephalitis (I) Antivirals Improved, full
recovery at 2
months
14 (M/
45)
Chik-CNS Fever,
arthralgia,
malaise,
diarrhoea
29 UL and LL paraesthesia;
flaccid areflexic
quadraparesis; impaired
UL and LL LT, PP; GCS
15
0 075 na GBS (II) IVIG ICU; improved
mRS 3
PLT 203
WCC 87
15 (M/
84)
Chik-CNS Fever, rash,
arthralgia,
malaise,
diarrhoea
4 Confusion, impaired
speech and swallow;
flaccid hyporeflexic
quadraparesis; myalgia;
GCS 8; MRI brain—
focal areas of
hyperintensity likely
related to
microangiopathy; NP—
inflammatory
myopathy
42 111 na Encephalitis (I),
Myositis
IVIG;
antivirals;
antibiotics;
antifungals
Ventilator-
associated
pneumonia; no
improvement,
mRS 5 at 6 weeksPLT 80
WCC 163
16 (M/
65)
Zika/Chik-
CNS
Fever, rash,
arthralgia,
malaise
0 LL paraesthesia; flaccid
areflexic paraparesis;
T11 sensory level;
impaired LL sensation
LT, PP, Vi, Pr; urinary
retention; GCS 15; MRI
brain and spine normal;
NP—AMSAN
10 108 na Myeloradiculitis
(I)
IVIG; steroids No improvement
at 3 weeks
PLT 130
WCC 99
17 (F/
19)
Zika/Chik-
Syst
Rash 41 UL and LL paraesthesia;
quadraparesis,
hyporeflexic LL; GCS
15; CT brain normal;
NP—AMAN; patient 19
weeks pregnant at
admission, foetus
diagnosed with Dandy-
Walker syndrome
2 023 - GBS (II) IVIG No improvement
at 3 weeksPLT 537
WCC 90
18 (F/
56)
Chik-CNS,
Zika-Syst
Fever, rash,
malaise
4 LL paraesthesia; flaccid
areflexic quadraparesis;
impaired UL & LL LT,
PP, Vi, Pr; C7 sensory
level; urinary retention;
GCS 15; MRI brain and
spine normal; NP—
AMSAN
0 071 na Myeloradiculitis
(II)
IVIG; steroids No
improvement,
mRS 5 at 1
month
PLT 340
WCC 150
(Continued)
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Outcome
Eight (36%; four with confirmed Zika) of the 22 patients required admission to an intensive
care unit; six (27%) needed intubation (including half the patients with GBS). Ten patients
were treated with intravenous immunoglobulin, two with corticosteroids, and seven with
Table 2. (Continued)
Patient Virological
Diagnosis
Systemic
Features
Prodrome
Length
(days)
Neurological Features CSF
WCC
CSF
Protein
Anti-
ganglioside
Antibody
Neurological
Diagnosis (levels
of certainty)
Management Progress and
Outcome
19 (M/
62)
Chik-CNS,
Dengue-Syst
Fever, rash 8 LL paraesthesia;
normotonic
hyperreflexic
paraplegia; extensor
plantars; impaired LL
Vi; T6-8 sensory level;
urinary incontinence;
GCS 15; CT brain
normal, MRI brain and
spine normal; NP—
AIDP
16 109 - Myeloradiculitis
(I)
IVIG; steroids Improved, mRS
2 at 1 monthPLT 680
WCC 188
20 (M/
17)
Chik-Syst Fever, rash 16 L sided numbness (LL,
UL, truncal); L
hemiparesis; L UMN
facial nerve palsy;
headache; impaired L
sided UL & LL LT, PP;
GCS 15; MRI brain—
demyelinating lesions R
parietal lobe &
thalamus consistent
with ADEM
na 044 na ADEM IVIG; steroids Improved, mRS
2 at 3 weeksPLT 362
WCC 63
21 (F/
67)
Chik-Syst Fever,
arthralgia
7 Flaccid areflexic
quadraparesis;
dysphagia; palatal
weakness; dyspnoea;
impaired UL & LL Pr,
LL Vi; GCS 15; CT
brain normal; NP—
AMSAN
10 071 - GBS (I) IVIG x 2 ICU; intubated;
no improvement,
mRS 5 at 2 weeksPLT 397
WCC 89
22 (F/
52)
Zika-CNS Fever 0 LL and R facial
numbness, impaired co-
ordination; headache,
diplopia; GCS 15; MRI
brain—signal
abnormality involving
frontal and parietal
lobes, pons and right
cerebellar peduncle
6 037 GD1a Encephalitis Steroids Improved, mRS
0 at 2 monthsPLT 412
WCC 102
Prodrome length = interval between onset of infection and neurological illness; Chik = chikungunya; CNS = virus detected in central nervous system, Syst = virus
detected systemically (i.e. outside CNS) only; PLT = platelet count x109/L, WCC = white cell count (systemic x109/L, CSF /μL); L = left, R = right, LL = lower limb,
UL = upper limb, CSF = cerebrospinal fluid, LMN = lower motor neuron, UMN = upper motor neuron, LT = light touch, PP = pinprick, Vi = vibration,
Pr = proprioception, GCS = Glasgow coma scale; MRI = magnetic resonance imaging, CT = computed tomography, NP = neurophysiology; AMSAN = acute motor and
sensory axonal neuropathy; AMAN = acute motor axonal neuropathy; AIDP = acute inflammatory demyelinating polyneuropathy; GBS = Guillain-Barre´ syndrome,
ADEM = acute disseminated encephalomyelitis; IVIG = intravenous immunoglobulin; ICU = intensive care unit admission, mRS = modified Rankin Scale; "na" = not
available. For neurological diagnoses the levels of diagnostic certainty are indicated I-III (highest to lowest), as per the Brighton and other criteria (appendix). The time
post-onset of neurological symptoms is given for outcomes, where known.
Although the GCS score was 15, the clinical features and imaging indicated focal encephalitis.
https://doi.org/10.1371/journal.pntd.0006212.t002
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both; four with encephalitis received aciclovir as presumptive treatment for herpes simplex
virus encephalitis. Four patients developed hospital acquired infections, including ventilator-
associated pneumonia and sacral osteomyelitis secondary to immobility. Fourteen (of 21 with
outcome data, 67%; six with confirmed Zika) patients improved; one with evidence of Zika +/-
dengue infection of the CNS deteriorated rapidly and died.
Discussion
With 84 countries or territories now affected by Zika virus,[29] increasing reports of associ-
ated neurological disease other than GBS,[10–13, 15, 16] and growing concern about coin-
fections with other arboviruses,[30] there is an urgent need to determine the full spectrum of
Zika’s neurological complications and its relationship with other arboviruses. In our study,
which begins to address these questions, over half of the patients with Zika virus infection
had presentations other than GBS, suggesting that these complications may be more impor-
tant than recognised previously. Patients had involvement of the meninges, brain paren-
chyma, spinal cord, and peripheral nerves in various combinations, as evidenced by the
clinical features, imaging and neurophysiological findings, and as has been described for
other flaviviruses.[9]
Four patients with evidence of Zika virus infection also had CNS infection with chikungu-
nya virus. Ten further patients negative for Zika tested positive for chikungunya. In South
America, reports of neurological disease associated with chikungunya virus are scarce, which
may reflect a lack of awareness among clinicians about the potential to affect the nervous sys-
tem, or the relatively recent arrival of the virus. Interestingly, in one patient (patient 17) virus
was detected 30 days after the onset of neurological disease, suggesting a persistent infection or
a late coincidental infection. In our study of patients from Rio de Janeiro, chikungunya virus
was as important a cause of neurological disease as Zika virus. Its importance in other settings
where Zika virus is assumed to be the cause of febrile illness, with or without neurological dis-
ease, needs to be assessed urgently.
We are only now beginning to understand the full spectrum of neurological syndromes
associated with both Zika and chikungunya infections. For example, patient 19 showed clinical
signs of myeloradiculitis and had neurophysiological evidence of AIDP, which is consistent
with simultaneous diagnoses of both myelopathy and a form of GBS. Another patient (15) had
an unusual combination of encephalitis, cerebral microangiopathy demonstrated on MRI and
inflammatory myopathy based on neurophysiological studies. We saw evidence of extensive
Box 1 Clinical presentation of encephalomyelitis (with subclinical
meningitis) associated with Zika and chikungunya virus infections
(patient 9)
The initial symptoms of arboviral infection included fever (82% of the patients), rash
(68%), malaise (55%) and arthralgia (50%). Two patients had diarrhoea in the month
preceding their neurological illness (Table 2); no patient reported a preceding lower
respiratory tract infection or conjunctivitis. Five (patients 11, 13, 15, 16, 22) reported
previous dengue. One (patient 22) reported prior vaccination against yellow fever. The
median (range) time between infective symptoms and onset of neurological disease was
65 (0–41) days. Patients presented with a range of neurological syndromes affecting the
CNS, peripheral nervous system, or both, as detailed in Table 2.
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intramedullary myelitis in some patients, and anterior myelitis in another (e.g. patients 2 and 9
respectively, Fig 3); the latter is consistent with anterior horn cell disease seen in other
Table 3. Clinical characteristics of 22 patients presenting with neurological disease associated with Zika, chikungunya and/or dengue virus infection.
n (%) or median (IQR)
All patients
(n = 22)
CNS disease (n = 11) PNS disease (n = 7) CNS & PNS disease (n = 4)
Age (years) 515 (35–645) 51 (28–675) 41 (35–555) 625 (605–635)
Males 11 (50%) 5 (45%) 3 (43%) 3 (75%)
Previous yellow fever vaccination (of 12 patients) 1 (8%) 1 of 4 (25%) 0 of 4 (0%) 0 (0%)
Previous dengue (of 20 patients) 5 (25%) 4 (36%) 0 of 5 (0%) 1 of 3 (33%)
Co-morbidity (of 20 patients) 10 (50%) 5 (45%) 2 of 6 (33%) 3 of 3 (100%)
Diabetes mellitus (type II) 2 (10%) 2 (18%) 0 of 6 (0%) 0 of 3 (0%)
Stroke 2 (10%) 0 (0%) 2 of 6 (33%) 0 of 3 (0%)
Hypertension 6 (30%) 3 (27%) 0 of 6 (0%) 3 of 3 (100%)
Hypercholesterolaemia 2 (10%) 1 (9%) 1 of 6 (17%) 0 of 3 (0%)
Cancer 2 (10%) 1 (9%) 0 of 6 (0%) 1 of 3 (33%)
Asthma 1 (5%) 1 (9%) 0 of 6 (0%) 0 of 3 (0%)
Cardiac disease 1 (5%) 0 (0%) 1 of 6 (17%) 0 of 3 (0%)
Neurological disease (Tourette’s syndrome) 1 (5%) 1 (9%) 0 of 6 (0%) 0 of 3 (0%)
Systemic features
Fever 18 (82%) 9 (82%) 5 (71%) 4 (100%)
Rash 15 (68%) 7 (64%) 4 (57%) 4 (100%)
Arthralgia 11 (50%) 6 (55%) 3 (43%) 2 (50%)
Malaise 12 (55%) 5 (45%) 4 (57%) 3 (75%)
Diarrhoea 2 (9%) 1 (9%) 1 (14%) 0 (0%)
Prodrome length (days) 55 (25–115) 4 (05–65) 12 (85–21) 3 (15–5)
Neurological symptoms
Weakness 19 (86%) 9 (82%) 6 (86%) 4 (100%)
Sensory disturbance 17 (77%) 7 (64%) 6 (86%) 4 (100%)
Neurological examination (of 21 patients)
Cranial nerve involvement 6 (29%) 2 of 10 (20%) 4 (57%) 0 (0%)
Sensory level 8 (38%) 4 of 10 (40%) 0 (0%) 4 (100%)
GCS<15 on admission 8 (38%) 6 of 10 (60%) 1 (14%) 1 (25%)
Diminished or absent reflexes 11 (52%) 2 of 10 (20%) 6 (86%) 3 (75%)
Brisk reflexes 6 (29%) 4 of 10 (40%) 1 (14%) 1 (25%)
Lumbar puncture results
CSF white cell count (of 21 patients) 4 (0–11) 105 (45–705) 1 (0–2) 5 (0–115)
CSF protein 835 (4425–111) 45 (364–1115) 75 (70–133.2) 100 (868–1083)
Treatment
IVIG 17 (77%) 6 (55%) 7 (100%) 4 (100%)
Steroids 9 (41%) 6 (55%) 0 (0%) 3 (75%)
Outcome
Responded to treatment (of 21 patients) 14 (67%) 7 of 10 (70%) 5 (71%) 2 (50%)
Admitted to ICU 8 (36%) 3 (27%) 4 (57%) 1 (25%)
Intubated 6 of 21 (29%) 2 of 10 (20%) 3 (43%) 1 (25%)
Died 1 (5%) 1 (9%) 0 (0%) 0 (0%)
CNS = central nervous system; PNS = peripheral nervous system. For certain parameters we did not have data for all patients; the number of patients for whom data was
available is indicated in brackets.
https://doi.org/10.1371/journal.pntd.0006212.t003
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flavivirus infections.[31] In the French Polynesian study, neurophysiological investigations
showed that all Zika patients with GBS had the AMAN subtype;[4] whereas in the Colombian
study, almost all had AIDP.[5] In our study we additionally found AMSAN, confirming
involvement of the sensory axons in Zika virus-associated GBS. One patient with AMSAN had
anti-GD1a antibodies, which is more normally associated with AMAN. Anti-GD1a antibodies
were also detected in Zika and chikungunya patients with central nervous system disease
(Table 2). We also found anti-GM1, anti-GD1b, and anti-GQ1b antibodies in patients with
central nervous system disease. Anti-GM1 antibodies are associated with AMAN, anti-GD1b
with sensory ataxic neuropathy, and anti-GQ1b with Miller Fisher syndrome and Bickerstaff’s
Fig 3. Central nervous system (CNS) imaging abnormalities in patients with evidence of Zika, chikungunya and/or dengue virus infection. A: Encephalomyelitis in a
patient with CNS Zika and systemic dengue infection (patient 3). Fluid attenuation inversion recovery [FLAIR] signal abnormality involving the middle cerebellar
peduncles, more marked on the right (axial scan). B: Acute disseminated encephalomyelitis in a patient with systemic chikungunya infection (patient 20). Confluent areas
of T2 signal abnormality suggesting neuroinflammation consistent with demyelination (coronal scan). C, D, E: Encephalomyelitis with subclinical meningitis in a patient
with CNS Zika + chikungunya infection (patient 9). FLAIR signal abnormality involving the medial temporal lobes, amygdala, and a small area of abnormality adjacent to
the temporal horn of the left lateral ventricle (C, axial scan). High signal intensity on T2-weighted images in the anterior medulla, and anterior cervical and thoracic cord
(D and E, sagittal scans). F, G, H: Myelitis in a patient with CNS Zika + dengue and systemic chikungunya infection (patient 2). Extensive intramedullary signal
abnormality of the cervical cord, without evidence of contrast enhancement (F, sagittal T2-weighted scan; G, sagittal T1-weighted scan with gadolinium; H, axial
T2-weighted scan). I, J: Facial diplegia with paraesthesia in patient with CNS Zika + chikungunya infection (patient 4). Bilateral facial nerve enhancement on T2-weighted
images with gadolinium (axial scan).
https://doi.org/10.1371/journal.pntd.0006212.g003
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brainstem encephalitis.[32] The significance of detecting these antibodies in patients with
encephalitis and myelitis is not certain.
Although in our study six patients had evidence of recent systemic dengue virus infection,
five of them also had evidence of CNS infection with a different virus, suggesting dengue on its
own was less likely to be the cause of the neurological disease. We might have expected to see
more dengue-associated neurology, given that the virus is circulating widely in Rio de Janeiro
[33] and is a well-recognised cause of neurological disease.[22] Whether this in some way
reflects the fact that it has been circulating for over 30 years in this city,[34] but Zika and chi-
kungunya viruses have been newly introduced, is not known. Alternatively, this may be due to
differing neurovirulence of the three viruses.
For dengue, secondary infection is a risk factor for more severe systemic dengue disease, a
phenomenon thought to be mediated by antibody-dependent enhancement.[35] Interestingly,
in a recent in vitro study, plasma immune to dengue virus induced potent antibody-dependent
enhancement of Zika virus.[36] In our cases, all serum samples were positive for dengue IgG
antibody, indicating prior flavivirus exposure, a pattern also seen in 86% of tested patients in
the Colombian report on GBS.[5] Larger prospective studies are needed to investigate whether
such dengue exposure is a risk factor for developing neurological disease after Zika virus
infection.
Combined infection of arboviruses has not been well described in those with neurological
presentations. In our patients with evidence of dual infections, whether the neurological dis-
ease was caused by one arbovirus or the other, or by a combination of the two is unclear. The
fact that so many of our patients had evidence of dual infection may indicate that combined
infections are responsible for severe disease, as we have seen in other settings.[37]
Flaviviruses can cause neurological disease by attacking the nervous system directly or indi-
rectly via immune-mediated processes; the latter tend to occur some time after the acute infec-
tion, making virological diagnosis especially challenging. Detection of virus in the CSF is
usually taken as the strongest evidence of causality, but it has often cleared by the time patients
present, making us reliant on detection of virus systemically or demonstration of CSF or
serum IgM antibody. For both Zika and chikungunya, whether testing urine for RNA increases
the window of detection compared to serum is debated.[38–40] In our series, six patients (two
with CNS disease) with no virus in the CSF or serum had virus detected in the urine (five Zika,
one chikungunya), underscoring the value of testing this sample.
Our results must be interpreted in the context of the study’s limitations. First, cross-reactiv-
ity between flaviviruses makes distinguishing Zika from dengue by serological tests challeng-
ing.[4, 8] In four patients (two of whom were positive for Zika by PCR), we found elevated
IgM antibody to both dengue and Zika, which may represent cross reactivity. Even in cases
where CSF IgM was detected for Zika but not dengue virus, given the unknown specificity and
sensitivity of the available flavivirus serological tests, caution must be applied. Newer assays in
development and plaque reduction neutralization testing will help in the future. Differentiat-
ing infections clinically was also difficult; conjunctivitis is commonly seen in Zika[1] and not
often reported for dengue or chikungunya, but we did not find conjunctivitis or any other clin-
ical features that could distinguish the infections in our series. We did not look for West Nile
virus because it was not circulating in Rio de Janeiro at the time of our study, but this may be
important in other settings. Second, given the retrospective nature of the study, we did not
have all CSF, serum and urine samples for each patient, thus potentially under-diagnosing
arboviral infections in the cohort; in addition, the timing of sample collection was not stan-
dardised. Third, we only studied patients who had symptoms consistent with Zika infection.
Whether Zika virus can case neurological disease in patients with no febrile illness will need to
be addressed in future studies. Fourth, our study included a relatively small number of
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patients, thus the spectrum of neurology and role of chikungunya described may be even more
extensive.
In summary, our study adds to the growing body of evidence arguing for a wide spectrum
of neurological disease associated with Zika virus infection, including central nervous system
disease. Some patients in whom a Zika virus-associated neurological disorder was suspected
were actually infected with chikungunya virus, and many were infected with more than one
arbovirus. The Zika public health emergency was recently declared over, recognising that the
virus is here to stay and a sustained technical and research response is needed.[7] To under-
stand fully the disease burden of Zika virus, clinicians and public health officials need to look
beyond GBS, and also to investigate for other arboviruses that may cause similar neurological
disease, particularly chikungunya.
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